Search

file (14) (1)

Investor Overview

Investor Overview

HOMEInvestor Overview

Read More

2024.Dec.31

News

OBI Pharma's OBI-992 Research Paper Selected as a First Disclosure Article Featured in Molecular Cancer Therapeutics Journal

2024.Dec.23

News

OBI Pharma Enters Collaboration with GlyTech to Expand GlycOBI® Enabling Technologies Outreach in Japan and to Advance Glycan Production

2024.Dec.11

News

OBI Pharma Earns Sports Enterprise Certification Again
Building a Healthy Workplace and Fulfilling Sustainability Commitments

Read More

2025.Jan.03

Announcement

OBI completed the capital reduction registration for the Restricted Stock Awards cancelled

2024.Dec.23

Announcement

OBI Pharma and GlyTech have entered into a GlycOBI marketing agreement in Japan and a material transfer agreement

2024.Dec.10

Announcement

Announcement on behalf of OBIGEN to acquire the worldwide intellectual property rights of OBI-858 and sign the technology transfer agreement

2023 Annual Report

Learn how we created value in 2023 and worked to pursue our purpose of enabling a healthier world.

Download PDF
Read More

Featured
Presentation

2024 Investors' Meeting - Innovation and Optimism

Download PDFAnnual Report

Read More

2024 Annual Shareholders’ Meeting

  • 2024.Jun.17 at 09:00 AM
  • Masterlink Securities Education and Training Center

Governance

Read More

Corporate
Overview​

Board of
Directors​

Special ​
Committee​

Integrity​

Internal
Audit​

Governance
Document​

Investor Relations

Contact